Holen Sie sich die Stockscreener-App
2.10
0.94%
-0.02
Handel nachbörslich:
2.11
0.010
+0.48%
Schlusskurs vom Vortag:
$2.12
Offen:
$2.14
24-Stunden-Volumen:
2.41M
Relative Volume:
0.93
Marktkapitalisierung:
$346.32M
Einnahmen:
$101.21M
Nettoeinkommen (Verlust:
$-569.00K
KGV:
-105.00
EPS:
-0.02
Netto-Cashflow:
$-56.88M
1W Leistung:
+2.44%
1M Leistung:
-12.13%
6M Leistung:
+221.69%
1J Leistung:
+68.00%
1-Tages-Spanne:
$2.02
$2.15
1-Wochen-Bereich:
$1.99
$2.17
52-Wochen-Spanne:
$0.40
$3.095
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Firmenname
Cytomx Therapeutics Inc
Sektor
Branche
Telefon
650.515.3185
Adresse
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Vergleichen Sie CTMX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
2.10 | 343.02M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-05-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-05-06 | Hochstufung | Jefferies | Hold → Buy |
| 2024-04-22 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-11-14 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-07 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-07-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-01-18 | Hochstufung | Barclays | Underweight → Overweight |
| 2021-11-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-28 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-03-29 | Eingeleitet | JP Morgan | Overweight |
| 2021-03-23 | Hochstufung | Jefferies | Hold → Buy |
| 2020-09-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-06-01 | Herabstufung | Jefferies | Buy → Hold |
| 2020-05-14 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-24 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Equal Weight |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-11-11 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-05-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-03-11 | Eingeleitet | Barclays | Overweight |
| 2018-11-26 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-10-15 | Eingeleitet | Goldman | Neutral |
| 2018-09-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-06-01 | Eingeleitet | SunTrust | Buy |
| 2018-01-05 | Eingeleitet | Citigroup | Buy |
| 2017-09-08 | Eingeleitet | Wedbush | Outperform |
| 2017-03-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2017-01-03 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2015-11-02 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Cytomx Therapeutics Inc Aktie (CTMX) Neueste Nachrichten
Real time social sentiment graph for CytomX Therapeutics Inc.July 2025 Trends & Stock Portfolio Risk Management - Newser
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2025 Earnings Call Transcript - MSN
Published on: 2025-09-03 09:30:47 - Newser
How to recover losses in CytomX Therapeutics Inc. stockEntry Point & Free Community Consensus Stock Picks - Newser
What earnings revisions data tells us about CytomX Therapeutics Inc.Weekly Stock Recap & Long-Term Growth Plans - Newser
CytomX Therapeutics Inc.’s volatility index tracking explainedJuly 2025 Chart Watch & Free Weekly Chart Analysis and Trade Guides - Newser
Published on: 2025-09-03 13:30:24 - beatles.ru
What earnings revisions data tells us about CytomX Therapeutics IncJuly 2025 Levels & Weekly Momentum Stock Picks - Newser
Will CytomX Therapeutics Inc. benefit from macro trends2025 Key Lessons & AI Based Buy/Sell Signal Reports - Newser
Can you recover from losses in CytomX Therapeutics Inc.Fed Meeting & Fast Gain Stock Trading Tips - Newser
CytomX Therapeutics Inc. stock trendline breakdownJuly 2025 Action & Momentum Based Trading Ideas - Newser
How to forecast CytomX Therapeutics Inc. trends using time seriesTrade Performance Summary & Free Low Drawdown Momentum Trade Ideas - Newser
Will CytomX Therapeutics Inc. stock recover after recent drop2025 Analyst Calls & Consistent Profit Trading Strategies - Newser
Sentiment analysis tools applied to CytomX Therapeutics Inc.Weekly Investment Summary & Consistent Income Trade Ideas - Newser
Is CytomX Therapeutics Inc. showing signs of accumulationWeekly Profit Recap & Verified Technical Trade Signals - Newser
Leading vs lagging indicators on CytomX Therapeutics Inc. performanceJuly 2025 Trends & Stepwise Trade Signal Guides - Newser
Will Windtree Therapeutics Inc. outperform during market ralliesJuly 2025 Short Interest & Fast Moving Trade Plans - خودرو بانک
Can CytomX Therapeutics Inc. maintain sales growthMarket Volume Report & Smart Investment Allocation Tips - khodrobank.com
Market Outlook: Will CytomX Therapeutics Inc. benefit from AI trendsJuly 2025 Gainers & Free Expert Approved Momentum Trade Ideas - khodrobank.com
Historical volatility pattern of CytomX Therapeutics Inc. visualized2025 Technical Patterns & Long-Term Safe Investment Plans - Newser
Is CytomX Therapeutics Inc. trading at a discountJuly 2025 Patterns & AI Enhanced Market Trend Forecasts - khodrobank.com
Will CytomX Therapeutics Inc. bounce back from current supportPortfolio Risk Report & Safe Entry Trade Signal Reports - Newser
Statistical indicators supporting CytomX Therapeutics Inc.’s strengthWeekly Profit Report & AI Based Buy and Sell Signals - Newser
Is CytomX Therapeutics Inc. benefiting from innovation trendsJuly 2025 Reactions & Weekly Top Stock Performers List - khodrobank.com
Does CytomX Therapeutics Inc. meet Warren Buffett’s criteriaJuly 2025 Momentum & Long-Term Growth Portfolio Plans - khodrobank.com
Volume Summary: Will CytomX Therapeutics Inc. benefit from AI trendsLong Setup & AI Forecasted Entry and Exit Points - khodrobank.com
Tools to assess CytomX Therapeutics Inc.’s risk profileInflation Watch & Technical Pattern Based Buy Signals - Newser
Does CytomX Therapeutics Inc. fit your quant trading modelMarket Volume Report & Free Low Drawdown Momentum Trade Ideas - Newser
Can CytomX Therapeutics Inc. Rally Enough to Break Even2025 Valuation Update & Daily Entry Point Trade Alerts - beatles.ru
Can CytomX Therapeutics Inc. hit a new high this monthJuly 2025 Trends & Stepwise Trade Signal Implementation - Newser
Is CytomX Therapeutics Inc. stock bottoming outDip Buying & Risk Controlled Stock Alerts - Newser
Smart tools for monitoring CytomX Therapeutics Inc.’s price actionTrade Performance Summary & Verified High Yield Trade Plans - Newser
CytomX Therapeutics Inc. Approaches Psychological Resistance Level getLinesFromResByArray error: size == 0 - kangso.co.kr
Is CytomX Therapeutics Inc. forming higher highs and higher lows2025 Key Lessons & Risk Controlled Swing Alerts - kpenews.com
Finanzdaten der Cytomx Therapeutics Inc-Aktie (CTMX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cytomx Therapeutics Inc-Aktie (CTMX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ogden Christopher | Chief Financial Officer |
Jun 16 '25 |
Sale |
2.69 |
10,614 |
28,540 |
226,271 |
| Ogden Christopher | Chief Financial Officer |
Jun 13 '25 |
Sale |
2.95 |
1,641 |
4,841 |
199,385 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Jun 13 '25 |
Option Exercise |
0.00 |
37,500 |
0 |
286,136 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Jun 16 '25 |
Sale |
2.69 |
13,884 |
37,334 |
272,252 |
| McCarthy Sean A. | CEO |
Jun 13 '25 |
Option Exercise |
0.00 |
150,000 |
0 |
1,145,195 |
| McCarthy Sean A. | CEO |
Jun 16 '25 |
Sale |
2.69 |
55,511 |
149,264 |
1,089,684 |
| McCarthy Sean A. | CEO |
Mar 18 '25 |
Sale |
0.60 |
37,656 |
22,556 |
995,195 |
| Ogden Christopher | Chief Financial Officer |
Mar 18 '25 |
Sale |
0.60 |
8,551 |
5,122 |
201,026 |
| Chu Yu-Waye | Chief Medical Officer |
Mar 18 '25 |
Sale |
0.60 |
4,025 |
2,411 |
135,725 |
| ROWLAND LLOYD A | General Counsel |
Mar 18 '25 |
Sale |
0.60 |
10,203 |
6,112 |
120,594 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):